Overview

Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma

Status:
Recruiting

Trial end date:
2025-09-05

Target enrollment:

Participant gender:

Summary

This is a multicenter Phase 1b, open-label study to evaluate the pharmacokinetic, safety and efficacy of binimetinib and encorafenib co-administered to adolescent patients with BRAF V600-mutant advanced/metastatic melanoma. The study consists of a Safety Run-in Phase to determine the RDE (recommended dose in expansion), followed by an Expansion Phase.

Phase:

Phase 1

Details

Lead Sponsor:

Array BioPharma
Pfizer

Collaborator:

Pierre Fabre Laboratories